Peter Burema News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lonza divests two sites in France and Scotland By Mary Page Bailey | April 1, 2021 Lonza AG (Basel, Switzerland) has completed the sale of its sites in Ploermel, France and Edinburgh, Scotland to Next Pharma. Gordon Bates, President and Head of Small Molecules, Lonza said: “The strategic divestment of our Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies. In this context, as we close the divestment process, we are confident that NextPharma is well placed to develop and grow both sites to their full pot...

Lonza is to sell off two European sites to NextPharma in a deal that gives the contract development and manufacturing firm facilities to work with lipid oral dosage forms for the nutrition and pharma markets. The production sites in Ploermel in France and Edinburgh in the UK, employs around 260 and 130 permanent staff respectively and produces liquid-filled hard capsules (including Licaps) and softgels (including for high potent and hormonal products). “NextPharma is an established and well-respected company, with extensive experience in oral and topical finished...

(2) NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosage Forms Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextPharma to broaden technology offering into lipid finished dosage forms Centers of excellence employing a total of 390 staff offer expertise in Lipid Oral Dosage Forms including softgels and liquid-filled hard capsules for the pharma and nutrition markets Sustainable growth and people development a priority for both companies A French version of this release is also available Quote from Gordon Ba...